← Back to readingRETRACTED ARTICLE: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial - Nature MedicineNatureNRETRACTED ARTICLE: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial - Nature MedicineIn this randomized phase 3 trial, patients with treatment-naive stage III–IV nonsmall cell lung cancer who received sintilimab or pembrolizumab in combination with chemotherapy early in the day (before 15:00 h) experienced longer progression-free survival compared with those receiving late time-of-day infusions.Nature - Zhe HuangDomainnature.comAuthorZhe HuangPublishedFebruary 2, 2026Canonical URL/reading/retracted-article-time-of-day-immunochemotherapy-in-non-small-ce-a8de5169Open source page
NRETRACTED ARTICLE: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial - Nature MedicineIn this randomized phase 3 trial, patients with treatment-naive stage III–IV nonsmall cell lung cancer who received sintilimab or pembrolizumab in combination with chemotherapy early in the day (before 15:00 h) experienced longer progression-free survival compared with those receiving late time-of-day infusions.Nature - Zhe Huang
